Eyepoint Pharmaceuticals reported topline data from LUGANO, the first of two pivotal Phase 3 trials of DURAVYU in wet AMD. The readout marks a key late-stage st

Eyepoint Pharmaceuticals reported topline data from LUGANO, the first of two pivotal Phase 3 trials of DURAVYU in wet AMD. The readout marks a key late-stage step, with another pivotal study still to come; DME topline data are expected in late 2027.